Ethicon Endo-Surgery, Inc. v. Meyer

249 S.W.3d 513, 2007 WL 4462713
CourtCourt of Appeals of Texas
DecidedMarch 27, 2008
Docket2-05-071-CV
StatusPublished
Cited by9 cases

This text of 249 S.W.3d 513 (Ethicon Endo-Surgery, Inc. v. Meyer) is published on Counsel Stack Legal Research, covering Court of Appeals of Texas primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Ethicon Endo-Surgery, Inc. v. Meyer, 249 S.W.3d 513, 2007 WL 4462713 (Tex. Ct. App. 2008).

Opinions

OPINION ON MOTION FOR REHEARING

ANNE GARDNER, Justice.

On Appellee’s motion for rehearing, we withdraw our opinion and judgment of April 12, 2007, and substitute the following.

Introduction

This is a marketing-defect products liability case. The product in question is the TLC-55 linear cutter/surgical stapler designed, manufactured, and marketed by Appellant Ethicon Endo-Surgery, Inc. (“Ethicon”). Ethicon appeals from a jury verdict and judgment in favor of Appellee Dianne Meyer. The key question is whether the surgeon who used the TLC-55 on Meyer conclusively negated producing cause when he testified that he had independent knowledge of the risks of which Meyer claims Ethicon should have warned him. We answer “yes” to that question, reverse the trial court’s judgment, and render a take-nothing judgment.

Background

On February 7, 2000, Dr. Curtis Mosier performed an exploratory laparoscopy on Meyer in an attempt to find the cause of her generalized abdominal pain. On February 9, 2000, Dr. Mosier discovered that a loop of Meyer’s small bowel had herniated through the laparoscopy incision, lost its supply of oxygen, and burst.

That same day, Dr. Mosier performed a second laparoscopy on Meyer to repair the damage to her intestines by resectioning part of her small bowel. The resectioning involved removing a three-foot length of Meyer’s intestines and reconnecting the cut ends. Dr. Mosier performed the surgery with the assistance of a TLC-55 lin[515]*515ear cutter designed, manufactured, and marketed by Ethicon. A linear cutter is a surgical device that creates parallel lines of staples and cuts the tissue between the staple lines, all with one “firing” of the device. In this particular procedure, Dr. Mosier used the TLC-55 to staple and cut Meyer’s bowel on either side of the part to be removed. He then also used the TLC-55 to attach the remaining portion of the bowel together and create an “anastomo-sis” between the cut ends of the bowel by stapling, rather than suturing, them together and cutting an opening between them to restore the flow of bowel contents. Dr. Mosier testified that he “milked” or tested the anastomosis to ensure that gas and fluid could pass through the opening without leaking out of Meyer’s bowel. Dr. Mosier made sure the staples were holding and that there was no leakage, and he thought that the anastomosis was working well.

In the days following the surgery, Meyer’s condition first improved, then declined. By February 17, enteric fluid, or bowel content, was leaking out of the la-paroscopy incisions in Meyer’s abdomen. On February 21, 2000, Meyer was transferred to another hospital, where a second surgeon, Dr. George Shires, performed a third operation. Dr. Shires discovered that one of the staple lines from the February 9 anastomosis had “dehisced,” or separated, allowing bowel contents to leak into Meyer’s abdomen and cause a serious infection. As a result of the dehiscence and infection, Meyer underwent several additional surgical procedures and a lengthy hospitalization.

Meyer sued Dr. Mosier for medical negligence on August 31, 2001. On March 11, 2002 — two years and nineteen days after the February 9, 2000 surgery — Meyer amended her petition and sued Ethicon for products liability, alleging design, manufacturing, and marketing defects in the TLC-55. Meyer eventually settled with Dr. Mosier, dismissed other defendants, and proceeded to trial against Ethicon. A jury found that the TLC-55 was defectively marketed and awarded $538,281.73 in damages to Meyer,1 and the trial court entered judgment accordingly. On appeal, Ethicon argues, among other things, that Meyer’s claim was barred by limitations and that Dr. Mosier’s testimony regarding his independent knowledge of the risks of using a linear cutter/stapler conclusively negated producing cause with regard to the TLC-55’s alleged marketing defect.

Producing Cause

In the second part of its fourth issue, Ethicon argues that the evidence conclusively negated producing cause because Dr. Mosier testified that he had independent knowledge of the risks of using the TLC-55 even if Ethicon failed to warn him of those risks. We agree.

This is a legal sufficiency challenge. We will sustain a legal sufficiency challenge when the evidence establishes conclusively the opposite of a vital fact. Uniroyal Goodrich Tire Co. v. Martinez, 977 S.W.2d 328, 334 (Tex.1998), cert. denied, 526 U.S. 1040, 119 S.Ct. 1336, 143 L.Ed.2d 500 (1999); Robert W. Calvert, “No Evidence” and “Insufficient Evidence” Points of Error, 38 Tex L.Rev. 361, 362-63 (1960). In determining whether there is legally sufficient evidence to support the finding under review, we must consider evidence favorable to the finding if a reasonable fact-finder could, and disregard evidence con[516]*516trary to the finding unless a reasonable faet-finder could not. City of Keller v. Wilson, 168 S.W.3d 802, 827 (Tex.2005).2

A marketing defect occurs when a defendant knows or should know of a potential risk of harm presented by the product but markets it without adequately warning of the danger or providing instructions for safe use. Bristol-Myers Co. v. Gonzales, 561 S.W.2d 801, 804 (Tex. 1978); Benavides v. Cushman, Inc., 189 S.W.3d 875, 881 (Tex.App.-Houston [1st Dist.] 2006, no pet.); USX Corp. v. Salinas, 818 S.W.2d 473, 482 (Tex.App.-San Antonio 1991, writ denied) (op. on reh’g). A marketing defect cause of action consists of five elements: (1) a risk of harm that is inherent in the product or that may arise from the intended or reasonably anticipated use of the product must exist, (2) the product supplier must actually know or reasonably foresee the risk of harm at the time the product is marketed, (3) the product must possess a marketing defect, (4) the absence of the warning or instructions must render the product unreasonably dangerous to the ultimate user or consumer of the product, and (5) the failure to warn or instruct must constitute a causative nexus in the product user’s injury. Salinas, 818 S.W.2d at 482-83.

When a product’s user is aware of the possible risks involved with a product’s use but decides to use it anyway, the inadequacy of the product’s warning is not, as a matter of law, a producing cause of an injury resulting from such use. Stewart v. Janssen Pharmaceutica, Inc., 780 S.W.2d 910, 912 (Tex.App.-El Paso 1989, writ denied). In Janssen, the plaintiff suffered respiratory arrest after his anesthesiologist administered a drug manufactured by the defendant. Id. at 911. The anesthesiologist testified that he was aware of the risk of respiratory depression with any anesthetic, regardless of any warning from the manufacturer. Id. at 912. The court held that the anesthesiologist’s testimony negated producing cause as a matter of law. Id.; see also Boswell v. Burroughs Wellcome Co., No.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
249 S.W.3d 513, 2007 WL 4462713, Counsel Stack Legal Research, https://law.counselstack.com/opinion/ethicon-endo-surgery-inc-v-meyer-texapp-2008.